Analysis of Adverse Reactions and Nursing Programs for Drug Treatment of Functional Dyspepsia
Clinical trial study, observe the clinical efficacy and safety of Pingwei Capsule combined with flupentixol and melitracen in the treatment of functional dyspepsia of liver stagnation and spleen deficiency syndrome. Eighty patients who met the criteria for inclusion of functional dyspepsia of liver stagnation and spleen deficiency were randomly divided into the treatment group and the control group. The treatment group was given Pingwei capsule combined with flupentixol and melitracenol tablets. Piperazine to melitracen tablets. Four weeks later, the total scores of symptoms, syndrome scores, overall efficacy, Hamilton anxiety scale, and electrogastrogram parameters were compared before and after treatment. The final data was analyzed using SPSS 17.0 statistical software. The rank data was tested by rank sum test, the count data was analyzed by x2, and the measurement data was analyzed by t test. After treatment, the electrogastrogram parameters were compared before and after treatment (P<0.05). The electrogastrogram parameters after treatment between the two groups were compared (P<0.05), indicating that both groups can improve gastric motility, and the treatment group is better than the control group. group. Conclusion: Pingwei capsule combined with flupentixol and melitracen tablets in the treatment of functional dyspepsia of liver stagnation and spleen deficiency can significantly improve the main clinical symptoms and depression and anxiety, no obvious adverse reactions, safe and effective.